Tango Therapeutics

Tango Therapeutics is a company that states it is leveraging the principle of synthetic lethality to develop medicines that take direct aim at specific tumors, using an approach that starts and ends with patients to expand the reach of genetically targeted therapies. Its official website lists a Boston, Massachusetts address and telephone contact, and features news items including inducement grants under Nasdaq Listing Rule 5635(c)(4), participation in the 2026 Cantor Global Healthcare Conference, second quarter 2026 financial results, and an executive chair transition.

Tango Therapeutics describes its approach as leveraging the principle of synthetic lethality to develop medicines that take direct aim at specific tumors, using an approach that starts and ends with patients to expand the reach of genetically targeted therapies. Its official website lists a Boston, Massachusetts address and telephone contact, and features news items including inducement grants under Nasdaq Listing Rule 5635(c)(4), participation in the 2026 Cantor Global Healthcare Conference, second quarter 2026 financial results, and an executive chair transition.

Leveraging synthetic lethality to develop medicines that take direct aim at specific tumors, expanding the reach of genetically targeted therapies.

• 2020.08.18

  Reported2020.08.18

  Gilead and Tango expand cancer-therapy collaboration[3]吉利德与Tango扩大癌症疗法合作finance.yahoo.com

  Gilead Sciences and Tango Therapeutics announced an expansion of their existing collaboration focused on discovering, developing and commercializing targeted immune-evasion therapies for cancer.

Read more

1. 1Tango Therapeuticstangotx.com
2. 2Tango Therapeutics (United States)wikidata.org
3. 3吉利德与Tango扩大癌症疗法合作finance.yahoo.com